ArticleAntimicrobial agents and chemotherapy2022
GSK2556286 Is a Novel Antitubercular Drug Candidate Effective
Abstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Randomized, Placebo-Controlled, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Oral Doses of Novel Antitubercular Drug Candidate, GSK2556286, in Healthy Adults.Journal of clinical pharmacology · 2026Trial
- An adenylyl cyclase switch reroutes carbon from growth to virulence lipids inbioRxiv : the preprint server for biology · 2026Article
- Article
- Alpibectir-Ethionamide combination (AlpE) for the treatment of tuberculosis.Nature communications · 2026Article
- Lipid profiling in nontuberculous mycobacterial pulmonary disease based on geospatial locations and disease severity.ERJ open research · 2026Article
- Pyrimidine-Based Compounds in Tuberculosis Management: A Review of their Biological and Medicinal Importance.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2026Review
- Article
- Deconvoluting drug interactions usingAntimicrobial agents and chemotherapy · 2025Article
- Comprehensive perspectives of metal and metal-free C-H activation approaches in pyrimidines and related heteroarenes: scope, mechanistic insights, and synthetic utility.RSC advances · 2025Review
- Article
- Revolutionizing tuberculosis treatment: Breakthroughs, challenges, and hope on the horizon.Acta pharmaceutica Sinica. B · 2025Review
- Review
- Environmental fungi target thiol homeostasis to compete with Mycobacterium tuberculosis.PLoS biology · 2024Article
- Spectinamide MBX-4888A exhibits favorable lesion and tissue distribution and promotes treatment shortening in advanced murine models of tuberculosis.Antimicrobial agents and chemotherapy · 2024Article
- Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of tuberculosis.Antimicrobial agents and chemotherapy · 2024Article
- A Review of Antibacterial Candidates with New Modes of Action.ACS infectious diseases · 2024Review
- A modified BPaL regimen for tuberculosis treatment replaces linezolid with inhaled spectinamides.eLife · 2024Article
- Projected health and economic effects of a pan-tuberculosis treatment regimen: a modelling study.The Lancet. Global health · 2024Article
- Environmental sphagnum-associated fungi target thiol homeostasis to compete withbioRxiv : the preprint server for biology · 2024Article
- Exploiting cAMP signaling in Mycobacterium tuberculosis for drug discovery.Trends in microbiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Eric L NuermbergerCenter for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins Universitygrid.21107.35grid.471401.7grid.21107.35 School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0003-1440-9889
Maria Santos Martínez-MartínezDiseases of the Developing World, GlaxoSmithKline R+D Limited, Tres Cantos, Madrid, Spain.
Olalla SanzDiseases of the Developing World, GlaxoSmithKline R+D Limited, Tres Cantos, Madrid, Spain.
Beatriz UronesDiseases of the Developing World, GlaxoSmithKline R+D Limited, Tres Cantos, Madrid, Spain.
Jorge EsquiviasDiseases of the Developing World, GlaxoSmithKline R+D Limited, Tres Cantos, Madrid, Spain.
Heena SoniCenter for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins Universitygrid.21107.35grid.471401.7grid.21107.35 School of Medicine, Baltimore, Maryland, USA.
Rokeya TasneenCenter for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins Universitygrid.21107.35grid.471401.7grid.21107.35 School of Medicine, Baltimore, Maryland, USA.
Sandeep TyagiCenter for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins Universitygrid.21107.35grid.471401.7grid.21107.35 School of Medicine, Baltimore, Maryland, USA.
Si-Yang LiCenter for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins Universitygrid.21107.35grid.471401.7grid.21107.35 School of Medicine, Baltimore, Maryland, USA.
Paul J ConverseCenter for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins Universitygrid.21107.35grid.471401.7grid.21107.35 School of Medicine, Baltimore, Maryland, USA.
Helena I BoshoffTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Gregory T RobertsonMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.ORCID 0000-0001-7157-4034
Gurdyal S BesraInstitute of Microbiology and Infection, School of Biosciences, University of Birminghamgrid.6572.6, Birmingham, United Kingdom.
Katherine A AbrahamsInstitute of Microbiology and Infection, School of Biosciences, University of Birminghamgrid.6572.6, Birmingham, United Kingdom.
Anna M UptonTB Alliance: Global Alliance for Tuberculosis Drug Development, New York, New York, USA.
Khisimuzi MdluliTB Alliance: Global Alliance for Tuberculosis Drug Development, New York, New York, USA.
Gary W BoyleGSK: Research, GlaxoSmithKline R&D, Ware, United Kingdom.
Sam TurnerGSK: Research, GlaxoSmithKline R&D, Ware, United Kingdom.
Nader FotouhiTB Alliance: Global Alliance for Tuberculosis Drug Development, New York, New York, USA.
Nicholas C CammackDiseases of the Developing World, GlaxoSmithKline R+D Limited, Tres Cantos, Madrid, Spain.
Juan Miguel SilesDiseases of the Developing World, GlaxoSmithKline R+D Limited, Tres Cantos, Madrid, Spain.
Marta AlonsoDiseases of the Developing World, GlaxoSmithKline R+D Limited, Tres Cantos, Madrid, Spain.
Jaime EscribanoDiseases of the Developing World, GlaxoSmithKline R+D Limited, Tres Cantos, Madrid, Spain.
Joel LelievreDiseases of the Developing World, GlaxoSmithKline R+D Limited, Tres Cantos, Madrid, Spain.
Joaquin Rullas-TrincadoDiseases of the Developing World, GlaxoSmithKline R+D Limited, Tres Cantos, Madrid, Spain.
Esther Pérez-HerránDiseases of the Developing World, GlaxoSmithKline R+D Limited, Tres Cantos, Madrid, Spain.
Robert H BatesDiseases of the Developing World, GlaxoSmithKline R+D Limited, Tres Cantos, Madrid, Spain.
Gareth Maher-EdwardsGSK, Brentford, Middlesex, United Kingdom.
David BarrosDiseases of the Developing World, GlaxoSmithKline R+D Limited, Tres Cantos, Madrid, Spain.ORCID 0000-0002-4099-0438
Lluís BallellDiseases of the Developing World, GlaxoSmithKline R+D Limited, Tres Cantos, Madrid, Spain.
Elena JiménezDiseases of the Developing World, GlaxoSmithKline R+D Limited, Tres Cantos, Madrid, Spain.
Funding
Development Of New Chemotherapeutics For TuberculosisZIAAI000693 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BARRY, CLIFTON · 2009 to 2025
$20.1MAbstract
As a result of a high-throughput compound screening campaign using Mycobacterium tuberculosis-infected macrophages, a new drug candidate for the treatment of tuberculosis has been identified. GSK2556286 inhibits growth within human macrophages (50% inhibitory concentration [IC
Indexed as
Mycobacterium tuberculosisTuberculosisTuberculosis, Multidrug-ResistantAnimalsAntitubercular AgentsMacrophagesMiceMicrobial Sensitivity TestsAntitubercular AgentsGSK2556286mouseMycobacterium tuberculosispharmacologyrelapsetuberculosis
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.